| Similar Articles |
|---|
 |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.   |
Chemistry World
February 9, 2007
Victoria Gill |
Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo. |
Fast Company
August 8, 2011
Kate Rockwood |
AIDS Vaccine Conference Despite billions in annual research dollars, the quest for an AIDS vaccine remains elusive. |
| AskMen.com |
Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. |
Chemistry World
September 3, 2009
Sarah Houlton |
New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine. |
Wired
September 2002
Amanda Griscom |
Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science. |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
Popular Mechanics
September 2006
Ben Harder |
Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check. |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
Chemistry World
December 3, 2014
Maria Burke |
Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline. |
Chemistry World
October 23, 2014
Rebecca Trager |
US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences |
Salon.com
June 9, 2000
Arthur Allen |
Heart of darkness A team of Los Alamos researchers traces AIDS back to the 1930s, blowing a hole in the most recent theory about its origin. |
Chemistry World
July 8, 2010
Sarah Houlton |
Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
Chemistry World
January 19, 2015
Maria Burke |
Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine. |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
Scientific American
April 10, 2006
Christine Soares |
Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines. |
Chemistry World
August 5, 2015
Emma Stoye |
Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated. |
BusinessWeek
June 28, 2004
Amy Barrett |
Jonas Salk: He Put An End To Polio In the '50s, Dr. Jonas Salk moved with lightning speed to develop and test a vaccine for polio. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources. |
Chemistry World
November 19, 2009
Hayley Birch |
How HIV gives antibodies the slip New research helps explain why antibodies designed to disarm HIV don't work unless they hit their target spot on. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
BusinessWeek
April 1, 2010
Bennett & Randall |
Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
BusinessWeek
November 24, 2003
John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. |
Chemistry World
September 1, 2014
Maria Burke |
Experimental Ebola drug 'impressive' in animal trials In the hunt for a treatment for Ebola, a new study has shown that monkeys given the experimental drug ZMapp all survived infection with the virus. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
Popular Mechanics
December 1, 2006
Ben Harder |
Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides. |
Chemistry World
September 24, 2015 |
A new hope in HIV prevention New microbicide products could turn the tide against Aids for those who need it most: women in sub-Saharan Africa. Dinsa Sachan reports. |
Pharmaceutical Executive
December 1, 2005
Alana Klein |
Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance. |
The Motley Fool
May 31, 2006
Stephen D. Simpson |
Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note. |
Popular Mechanics
February 11, 2010
Adam Hadhazy |
The Truth About 9 Anti-Vaccine Studies Led by celebrities such as Jenny McCarthy, the anti-vaccine movement continues to vehemently oppose mainstream science's overwhelming consensus that vaccines do not cause developmental disorders. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Scientific American
October 2008
John Rennie |
Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed. |
Chemistry World
August 20, 2014
Maria Burke |
Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern. |
Managed Care
September 2006
Thomas Morrow |
Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases. |
Fast Company
June 2015 |
Meet Ebola's Soft-Spoken, Plant-Loving Arch Nemesis A professor at Arizona State University, Arntzen is considered the godfather of a growing field of research sometimes called "pharming": engineering plants to produce specialized vaccines and other drugs. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
Bio-IT World
May 7, 2002
Davies & Levitt |
Bridge Over Troubled Waterford Project For a project that links some of the best institutions and minds in AIDS research in order to produce an effective vaccine that could save millions of lives, funding should be a nonissue. Unfortunately, that is not the case -- and the bio-IT community has to find a way to remedy this issue. |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
Managed Care
June 2007
Thomas Morrow |
Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
BusinessWeek
February 10, 2011
Rob Waters |
Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology. |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
